What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His primary scientific interests are in Internal medicine, Lung cancer, Surgery, Chemotherapy and Oncology.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Mesothelioma.
His Lung cancer research incorporates themes from Cancer, Respiratory disease, Quality of life, Clinical endpoint and Disease.
His Surgery study integrates concerns from other disciplines, such as Clinical trial and Hazard ratio.
His Chemotherapy study which covers Pembrolizumab that intersects with Nivolumab and Anaplastic lymphoma kinase.
His Oncology research integrates issues from Carcinoma and Pathology.
His most cited work include:
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer (4177 citations)
- Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer (1165 citations)
- Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. (753 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Oncology, Lung cancer, Chemotherapy and Surgery.
His Internal medicine study frequently intersects with other fields, such as Gastroenterology.
His study in the field of Non small cell, non-small cell lung cancer and Erlotinib also crosses realms of In patient.
His work deals with themes such as Carcinoma, Randomized controlled trial, Disease and Hazard ratio, which intersect with Lung cancer.
His study on Chemotherapy is mostly dedicated to connecting different topics, such as Toxicity.
He works mostly in the field of Surgery, limiting it down to concerns involving Mesothelioma and, occasionally, Progressive disease.
He most often published in these fields:
- Internal medicine (74.93%)
- Oncology (53.89%)
- Lung cancer (40.92%)
What were the highlights of his more recent work (between 2014-2021)?
- Internal medicine (74.93%)
- Oncology (53.89%)
- Lung cancer (40.92%)
In recent papers he was focusing on the following fields of study:
Mary O'Brien mainly focuses on Internal medicine, Oncology, Lung cancer, Chemotherapy and Non small cell.
His biological study spans a wide range of topics, including Gastroenterology and Surgery.
His Surgery study combines topics in areas such as Immunohistochemistry, Adjuvant and Egfr mutation.
The Oncology study combines topics in areas such as Radiation therapy and Immunotherapy.
Lung cancer is a subfield of Pathology that Mary O'Brien investigates.
His research in Chemotherapy intersects with topics in Predictive value of tests, Quality of life and Hazard ratio.
Between 2014 and 2021, his most popular works were:
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer (4177 citations)
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater (386 citations)
- Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial (193 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Chemotherapy
His primary areas of investigation include Internal medicine, Oncology, Lung cancer, Chemotherapy and Surgery.
His Oncology research is multidisciplinary, incorporating perspectives in Pathology, Radiation therapy, Gemcitabine and Immunotherapy.
His studies deal with areas such as Positron emission tomography, Radiology, Clinical trial and Randomized controlled trial as well as Lung cancer.
His research investigates the connection between Chemotherapy and topics such as Anaplastic lymphoma kinase that intersect with issues in ROS1.
His Surgery research is multidisciplinary, incorporating elements of Immunohistochemistry, Cancer and Hazard ratio.
His study in Pembrolizumab is interdisciplinary in nature, drawing from both Combination chemotherapy, Carboplatin, Cisplatin, PD-L1 and Nivolumab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
